Hormone medicines
Triptorelin
A GnRH agonist used in specific hormone-suppression settings; the initial hormone rise and depot formulation matter.
Randomized prostate-cancer suppression comparison; historical formulation limits; checked 2026-10-01
Also known as: Trelstar · Decapeptyl
Practical use
Clinical purpose, evidence and review questions
- Know the clinical goal
- Separate biochemical suppression from cancer control and daily-life effects.
- Bring the formulation name
- Record the actual depot product with the treatment history.
- Track relevant changes
- Discuss fatigue, hot flashes, metabolic findings and new neurological or urinary symptoms with the oncology team.
Overview
Triptorelin initially stimulates GnRH receptors, then suppresses gonadotropin signaling with sustained exposure. This guide focuses on US Trelstar for advanced prostate cancer. Other products and age groups require their own labeling. Suppression in cancer care is not evidence of post-cycle hormone restoration.
Risks and limitations
Early testosterone elevation can worsen cancer-related symptoms, including urinary obstruction or spinal-cord compression. Longer-term concerns include metabolic changes, cardiovascular events, QT prolongation, seizures and severe skin reactions. New leg weakness, bladder dysfunction or severe back pain needs urgent assessment.
How to read this
Testosterone suppression, cancer progression, symptoms and survival are different endpoints. A rapid hormone fall is informative but does not by itself establish the best cancer treatment.
Research explained
Triptorelin versus leuprolide in advanced prostate cancer
Who was studied
284 men received triptorelin (140) or leuprolide (144) in a comparative randomized study following testosterone suppression and maintenance through approximately nine months.
What was found
Suppression to the study’s threshold occurred in 91.2% versus 99.3% at day 29 and 97.7% versus 97.1% at day 57. Later maintenance rates were comparable. A secondary nine-month survival difference favored triptorelin.
What it cannot establish
The short study’s main question was hormonal suppression. A secondary survival signal does not establish a durable survival advantage or superiority over modern cancer combinations.
Read the original studyEarly stimulation can precede suppression
The agonist’s initial action explains why clinicians monitor for symptom worsening before sustained suppression develops.
Supporting sourceA formulation is part of the medicine
Different Trelstar depots have distinct release characteristics. Results from one preparation should retain that identity.
Supporting sourceClaims versus findings
Incorrect
A GnRH agonist always raises testosterone.
Initial stimulation is followed by suppression under sustained exposure in the labeled cancer setting.
Check the evidenceCommon questions
Does the early suppression difference prove worse long-term cancer control?
No. Hormonal kinetics are not the same endpoint as long-term cancer progression or survival.
SourceSources
Triptorelin versus leuprolide in advanced prostate cancer
US prescribing information; checked October 1, 2026
Sources checked 2026-10-01.
General education; not a personal treatment plan.